OncoTherapy Science, Inc. (4564.T)
JPY 25.0
(8.7%)
JPY 25.0
(8.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.28 Billion JPY | -1.16% |
| 2022 | -1.09 Billion JPY | 26.96% |
| 2021 | -2.03 Billion JPY | 7.83% |
| 2020 | -1.58 Billion JPY | 20.94% |
| 2019 | -2.15 Billion JPY | 9.29% |
| 2018 | -2.56 Billion JPY | 19.73% |
| 2017 | -2.84 Billion JPY | 0.95% |
| 2016 | -2.91 Billion JPY | 3.4% |
| 2015 | -2.85 Billion JPY | -24.42% |
| 2014 | -1.85 Billion JPY | 34.88% |
| 2013 | -3.68 Billion JPY | -240.35% |
| 2012 | -979 Million JPY | -183.97% |
| 2011 | 1.3 Billion JPY | 223.89% |
| 2010 | 773.97 Million JPY | -10.68% |
| 2009 | 693.32 Million JPY | 147.02% |
| 2008 | 147.17 Million JPY | 151.29% |
| 2007 | -270.88 Million JPY | 69.35% |
| 2006 | -1.23 Billion JPY | -61.19% |
| 2005 | -722.38 Million JPY | -696.34% |
| 2004 | 91.39 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -290.26 Million JPY | 92.97% |
| 2023 Q3 | -277.99 Million JPY | 10.29% |
| 2023 Q2 | -309.88 Million JPY | 19.22% |
| 2023 Q1 | -383.62 Million JPY | -91.06% |
| 2023 Q4 | -162.45 Million JPY | 41.56% |
| 2023 FY | - JPY | -1.16% |
| 2022 Q3 | -273.41 Million JPY | 10.22% |
| 2022 Q4 | -200.78 Million JPY | 26.56% |
| 2022 FY | - JPY | 26.96% |
| 2022 Q2 | -304.53 Million JPY | 11.56% |
| 2022 Q1 | -344.35 Million JPY | -32.46% |
| 2021 Q4 | -259.97 Million JPY | 58.22% |
| 2021 Q3 | -622.25 Million JPY | -879.89% |
| 2021 FY | - JPY | 7.83% |
| 2021 Q2 | -63.5 Million JPY | 89.56% |
| 2021 Q1 | -608.38 Million JPY | -64.07% |
| 2020 Q3 | -427.5 Million JPY | 2.73% |
| 2020 FY | - JPY | 20.94% |
| 2020 Q4 | -370.8 Million JPY | 13.26% |
| 2020 Q1 | -479.37 Million JPY | -6.37% |
| 2020 Q2 | -439.5 Million JPY | 8.32% |
| 2019 Q2 | -592.42 Million JPY | -0.61% |
| 2019 Q3 | -517.9 Million JPY | 12.58% |
| 2019 Q1 | -588.83 Million JPY | -7.85% |
| 2019 FY | - JPY | 9.29% |
| 2019 Q4 | -450.68 Million JPY | 12.98% |
| 2018 Q2 | -1.01 Billion JPY | -38.65% |
| 2018 FY | - JPY | 19.73% |
| 2018 Q4 | -545.96 Million JPY | -27.7% |
| 2018 Q1 | -731.05 Million JPY | 5.22% |
| 2018 Q3 | -427.55 Million JPY | 57.82% |
| 2017 Q1 | -615.08 Million JPY | 23.95% |
| 2017 FY | - JPY | 0.95% |
| 2017 Q4 | -771.29 Million JPY | 3.1% |
| 2017 Q3 | -795.93 Million JPY | 7.9% |
| 2017 Q2 | -864.18 Million JPY | -40.5% |
| 2016 FY | - JPY | 3.4% |
| 2016 Q2 | -736.42 Million JPY | 6.81% |
| 2016 Q4 | -808.78 Million JPY | -18.96% |
| 2016 Q3 | -679.85 Million JPY | 7.68% |
| 2016 Q1 | -790.24 Million JPY | -5.98% |
| 2015 Q4 | -745.64 Million JPY | 6.91% |
| 2015 FY | - JPY | -24.42% |
| 2015 Q1 | -806.13 Million JPY | -108.47% |
| 2015 Q2 | -801.67 Million JPY | 0.55% |
| 2015 Q3 | -801.02 Million JPY | 0.08% |
| 2014 Q1 | -431.93 Million JPY | 45.36% |
| 2014 FY | - JPY | 34.88% |
| 2014 Q2 | -914.31 Million JPY | -111.68% |
| 2014 Q3 | -807.45 Million JPY | 11.69% |
| 2014 Q4 | -386.69 Million JPY | 52.11% |
| 2013 Q1 | -1.06 Billion JPY | -326.6% |
| 2013 Q3 | -924.83 Million JPY | 12.32% |
| 2013 FY | - JPY | -240.35% |
| 2013 Q4 | -790.45 Million JPY | 14.53% |
| 2013 Q2 | -1.05 Billion JPY | 1.21% |
| 2012 Q2 | -385.05 Million JPY | 46.74% |
| 2012 Q1 | -723.01 Million JPY | -121.72% |
| 2012 FY | - JPY | -183.97% |
| 2012 Q3 | -461.46 Million JPY | -19.84% |
| 2012 Q4 | 471.2 Million JPY | 202.11% |
| 2011 Q4 | 3.32 Billion JPY | 619.96% |
| 2011 Q1 | -1.01 Billion JPY | -573.98% |
| 2011 Q2 | -505.8 Million JPY | 50.32% |
| 2011 Q3 | -640.21 Million JPY | -26.57% |
| 2011 FY | - JPY | 223.89% |
| 2010 Q1 | -743.14 Million JPY | -151.94% |
| 2010 Q2 | 339.17 Million JPY | 145.64% |
| 2010 Q3 | 591.76 Million JPY | 74.47% |
| 2010 Q4 | 214.79 Million JPY | -63.7% |
| 2010 FY | - JPY | -10.68% |
| 2009 Q1 | -728.81 Million JPY | -138.9% |
| 2009 FY | - JPY | 147.02% |
| 2009 Q4 | 1.43 Billion JPY | 635.44% |
| 2009 Q3 | 194.55 Million JPY | 143.78% |
| 2009 Q2 | -444.43 Million JPY | 39.02% |
| 2008 FY | - JPY | 151.29% |
| 2008 Q3 | -517.9 Million JPY | 0.0% |
| 2008 Q4 | 1.87 Billion JPY | 461.75% |
| 2007 FY | - JPY | 69.35% |
| 2006 FY | - JPY | -61.19% |
| 2005 FY | - JPY | -696.34% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 234.171% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -163.349% |
| GNI Group Ltd. | 14.48 Billion JPY | 108.872% |
| Linical Co., Ltd. | 1.24 Billion JPY | 203.068% |
| Trans Genic Inc. | 240.95 Million JPY | 633.506% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 5.19% |
| Soiken Holdings Inc. | -583.2 Million JPY | -120.418% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -113.151% |
| AnGes, Inc. | -8.86 Billion JPY | 85.491% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 82.626% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 1103.453% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -48.956% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -17.743% |
| CanBas Co., Ltd. | 53.65 Million JPY | 2496.028% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -65.744% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -1049.805% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | -6.087% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 6.904% |
| PeptiDream Inc. | 7.37 Billion JPY | 117.428% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 33.383% |
| Ribomic Inc. | -1.01 Billion JPY | -26.959% |
| SanBio Company Limited | -4.52 Billion JPY | 71.591% |
| Healios K.K. | -3 Billion JPY | 57.25% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -10.268% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 7.722% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 8.31% |
| StemRIM | -2.03 Billion JPY | 36.738% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 198.397% |
| FunPep Company Limited | -952 Million JPY | -35.031% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -44.639% |
| Stella Pharma Corporation | -723.85 Million JPY | -77.59% |
| TMS Co., Ltd. | -937 Million JPY | -37.192% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -65.786% |
| Cuorips Inc. | -518 Million JPY | -148.165% |
| K Pharma,Inc. | 366.05 Million JPY | 451.172% |
| Takara Bio Inc. | 8.02 Billion JPY | 116.021% |
| ReproCELL Incorporated | 8.24 Million JPY | 15691.183% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1561.817% |
| StemCell Institute Inc. | 534.35 Million JPY | 340.57% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 625.09% |
| CellSeed Inc. | -836.51 Million JPY | -53.672% |